<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490500</url>
  </required_header>
  <id_info>
    <org_study_id>2017-CHITS-07</org_study_id>
    <secondary_id>2018-A00070-55</secondary_id>
    <nct_id>NCT03490500</nct_id>
  </id_info>
  <brief_title>Using the S100B Protein for Emergency Headache Management Care</brief_title>
  <acronym>S100</acronym>
  <official_title>Improving the Headache Management Care in the Emergency Unit by Using a Biological Marker: S100B Protein.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the negative predictive value of protein S100B that
      could exclude subarachnoid and intracranial haemorrhage for patient that present severe
      headache within the last 3 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be proposed to every patient that correspond to eligibility criteria, such as
      presenting a severe headache (Visual Analog Scale ≥ 6/10) within 3 hours before arriving to
      the emergency.

      After signing the informed consent, a blood sample will be taken in order to dosage S100B
      protein of each patient, and then they will have a brain scan.

      The trial ends after the brain scan for each patient. Results of brain scans will be compared
      with results of S100B dosage.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the interest of PS100B dosage in the severe headache therapeutic management</measure>
    <time_frame>15 months</time_frame>
    <description>Negative predictive value of PS100B dosage below the reference value of 0.10 µG/L for intracerebral haemorrhage lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Intracranial Bleeding in patient with severe headache</measure>
    <time_frame>15 months</time_frame>
    <description>Incidence of intracranial bleeding in patient with severe headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of subarachnoid hemorrhage in patient with severe headache</measure>
    <time_frame>15 months</time_frame>
    <description>Incidence of subarachnoid haemorrhage in patient with severe headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of intracranial haemorrhage in migraine patient with severe headache at inclusion</measure>
    <time_frame>15 months</time_frame>
    <description>Incidence of intracranial haemorrhage in migraine patient with severe headache at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the number of lumbar puncture that could have been avoided</measure>
    <time_frame>15 months</time_frame>
    <description>The ratio of patient with a normal scan and a PS100 dosage &lt; 0.10µg/L, on patient eligible for lumbar puncture according to the usual practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the number of cerebral scan that could have been avoided</measure>
    <time_frame>15 months</time_frame>
    <description>The ratio of patient with a normal scan and a PS100 dosage &lt; 0.10 µg/L, on patient eligible for cerebral scan according to the usual practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the number of lumbar puncture's complications that could have been avoided.</measure>
    <time_frame>15 months</time_frame>
    <description>The ratio of patients with PS100 &lt; 0.10µg/L and normal cerebral scan on the total number of patients included</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Headache, Migraine</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>S100B protein dosage</arm_group_label>
    <description>Biological</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for protein S100B dosage
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population will be recruited in the emergency unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over 18 years-old

          -  Patient presenting at the Emergency Service a non-traumatic severe headache lasting
             for less than 3 hours. The severity is defined as a VAS ≥ 6/10

          -  Blood sample can be taken within 1 hour following the emergency admission

          -  VAS &gt; 6 or Glasgow &lt; 8

          -  Signed and dated informed consent by patient, or trusted person, or family

        Exclusion Criteria:

          -  Patient presenting headache after head trauma

          -  Pregnant or breastfeeding women

          -  Patient with a pathology causing the elevation of PS100B's rate such as Alzheimer's
             disease, Creuzfeld-Jacob's disease, Multiple Sclerosis, cerebral tumour, trisomy 21,
             melanoma (diabetes excluded)

          -  Patient covered by social security regimen or equivalent

          -  Patient under guardianship (legal protection)

          -  Patient deprived of liberty by court or administrative order

          -  Any condition that could influence PS100B's dosage results according to the physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélien Renard, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital d'Instruction des Armées Sainte Anne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anaïs Maugard</last_name>
    <phone>04.94.14.55.29</phone>
    <phone_ext>+33</phone_ext>
    <email>anais.maugardlandre@ch-toulon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mylène Vernisse</last_name>
    <phone>04.94.14.55.29</phone>
    <phone_ext>+33</phone_ext>
    <email>mylene.vernisse@ch-toulon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Laveran</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Olivier Vidal, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Sainte Anne</name>
      <address>
        <city>Toulon</city>
        <state>Var</state>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurelien Renard, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon La Seyne-sur-Mer</name>
      <address>
        <city>Toulon</city>
        <state>Var</state>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ambre Houllé, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):385-7.</citation>
    <PMID>16484650</PMID>
  </reference>
  <reference>
    <citation>Edlow JA, Panagos PD, Godwin SA, Thomas TL, Decker WW; American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute headache. Ann Emerg Med. 2008 Oct;52(4):407-36. doi: 10.1016/j.annemergmed.2008.07.001.</citation>
    <PMID>18809105</PMID>
  </reference>
  <reference>
    <citation>Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, Hoecherl EF, Jonas F, Marzi I, Leucht P, Jochum M, Mutschler W. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006 May;25(5):446-53.</citation>
    <PMID>16680008</PMID>
  </reference>
  <reference>
    <citation>Gilbert JW, Johnson KM, Larkin GL, Moore CL. Atraumatic headache in US emergency departments: recent trends in CT/MRI utilisation and factors associated with severe intracranial pathology. Emerg Med J. 2012 Jul;29(7):576-81. doi: 10.1136/emermed-2011-200088. Epub 2011 Aug 19.</citation>
    <PMID>21856709</PMID>
  </reference>
  <reference>
    <citation>Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin KR, Grotta JC, Shaw SG, Knudson L, Frankowski RF. Headache in the emergency department. Headache. 2001 Jun;41(6):537-41.</citation>
    <PMID>11437887</PMID>
  </reference>
  <reference>
    <citation>Edlow JA, Caplan LR. Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med. 2000 Jan 6;342(1):29-36. Review.</citation>
    <PMID>10620647</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>protein S100B</keyword>
  <keyword>negative predictive value</keyword>
  <keyword>headache</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no IPD sharing plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

